BARCELONA,
Spain , May 22,
2017 /PRNewswire/ -- Anaconda
Biomed, a pre-clinical stage medical device company focused on the
development of the next generation of neuro-thrombectomy systems
for the treatment of Acute Ischemic Stroke (AIS), today announces
it has closed a Series A financing of 15
million Euro. The leading investors include new investors
Ysios Capital (Barcelona, Spain),
Omega Funds (Boston, MA, USA),
Banco Sabadell (Spain) as well as
current investor Innogest Capital (Milan,
Italy).
In conjunction with the financing, Josep L. Sanfeliu, General Partner at Ysios
Capital, and Claudio Nessi, Managing
Director at Omega Funds will join Anaconda Biomed's Board of
Directors. Giovanni Leo, will
continue to represent Innogest Capital in Anaconda Biomed's Board
of Directors.
"This financing provides Anaconda Biomed the capital
necessary to substantially progress the development of our ANCD
BRAIN™ device, including the validation and
verification process, clinical studies to support the initial
commercialization of ANCD BRAIN™ in
Europe, and an initial submission
to FDA," said Ofir Arad, Co-Founder
and CEO of Anaconda Biomed. "Furthermore, the addition of
Josep L. and Claudio to our Board will strengthen the extensive
operational and financial expertise available to our management
team."
"The investment in Anaconda Biomed is great news not only
for the consolidation of the medtech ecosystem in Spain and Barcelona but also for the amazing work of the
founders in putting together a disruptive medical device
by combining excellent medicine with high tech chemistry,"
said Josep L. Sanfeliu partner at
Ysios Capital.
"We are very pleased for this sizable investment round
following our first seed investment in Anaconda Biomed's one year
ago," said Claudio Rumazza, Partner
at Innogest Capital. "With its innovative design addressing a clear
clinical need and a capable management team, Anaconda Biomed is
well positioned to be a winner in the high growth stroke treatment
market and a success story for European medtech
industry".
"Mechanical thrombectomy is quickly becoming a game
changing procedure for ischemic stroke patients," said Claudio Nessi, partner at Omega Funds. "Our
analysis suggests that Anaconda's innovative device may become
the next generation device and therefore a market
leader."
Additional investors include Banco Sabadell (Spain) and other investors.
Stroke is the fifth leading cause of death in the U.S. and
a leading cause of disability, according to the
American Heart Association/American Stroke Association
(AHA/ASA). Additionally, every 2 seconds
someone in the world is undergoing a stroke. Every 10 seconds
someone in the world dies from a stroke. In the USA alone, there are about 690,000 annual
incidences of AIS.
About Anaconda Biomed
Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most
innovative early stage medical technology companies. The company
was founded by Dr. Ofir Arad and Dr.
Marc Ribó in 2015, and is developing
the ANCD BRAIN™, a novel 3rd Generation
Stented Aspiration Thrombectomy System for the treatment of
Acute Ischemic Stroke (AIS). Learn more at:
www.anaconda.bio
About Ysios Capital
Ysios Capital is a leading Spanish venture capital firm
that provides private equity financing to early- and mid-stage
human healthcare and life science companies with a special focus on
pharmaceuticals, diagnostics and medical devices. Founded in 2008,
Ysios Capital currently has close to €200M ($220M) in assets under management. Ysios BioFund
II Innvierte was closed in September
2016 at €126.4M. For more information, please
visit: www.ysioscapital.com
About Innogest Capital
Innogest Capital is a venture capital firm with offices in
Milan, Turin and San
Francisco that focuses on promising early stage healthcare
ventures developing medical devices, diagnostics and digital
health. With over €200 million of capital under management Innogest
Capital is particularly active in cardiology, neurology and
oncology. Learn more at:
www.innogest.it
About Omega Funds
Omega Funds is a leading venture capital and growth equity
investor within the broad life sciences sector. Founded in 2004,
the firm is based in Boston and
has a strategic relationship with NeoMed Management, a Jersey
headquartered investment firm, which broadens its capabilities in
Europe. For further information,
please visit:
www.omegafunds.net
Forward-Looking Statements
This press release contains statements that are
"forward-looking statements" that are based upon management's
current expectations and assumptions and are subject to many risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated
herein.
Media Contact
Uri Fligil
Anaconda Biomed
Plaça Catalonia 1, 08002
Barcelona,
Spain
Tel: +34 936 397 710
Email: info@anaconda.bio
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anaconda-biomed-secures-15-million-euro-in-series-a-financing-led-by-ysios-capital-innogest-capital-and-omega-funds-300461710.html
SOURCE Anaconda BioMed, S.L.